Targeting RhoA/Rho Kinase and p21-Activated Kinase Signaling to Prevent Cancer Development and Progression

被引:26
作者
Chang, Yu-Wen E. [1 ]
Bean, Ronald R. [1 ]
Jakobi, Rolf [1 ]
机构
[1] Kansas City Univ Med & Biosci, Kansas City, MO 64106 USA
关键词
Cancer invasion; metastasis; RhoA; Rho kinase; ROCK; p21-activated kinase; PAK; adherens junctions; cell motility; apoptosis; anoikis; SQUAMOUS-CELL CARCINOMA; GTP-BINDING PROTEIN; GERANYLGERANYLTRANSFERASE-I INHIBITOR; ANCHORAGE-INDEPENDENT GROWTH; HUMAN PANCREATIC-CANCER; RHO-GTPASES; EPITHELIAL-CELLS; TUMOR-CELLS; GENE-EXPRESSION; GAMMA-PAK;
D O I
10.2174/157489209788452830
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Elevated RhoA/Rho kinase and p21-activated kinase signaling have been shown to promote cancer development and metastasis and have drawn much attention as potential targets of anti-cancer therapy. Elevated RhoA and Rho kinase activity promote cancer cell invasion and eventually lead to metastasis by disrupting E-cadherin-mediated adherens junctions and degradation of the extracellular matrix. Elevated p21-activated kinase activity promotes invasion by stimulating cell motility but also promotes cancer cell survival and growth. In this review we describe normal functions of RhoA/Rho kinase and p21-activated kinase signaling, mechanisms that lead to constitutive activation of RhoA/Rho kinase and p21-activated kinase pathways, and processes by which constitutive RhoA/Rho kinase and p21-activated kinase activity promote cancer development and progression to more aggressive and metastatic phenotypes. In addition, we summarize relevant patents on RhoA/Rho kinase and p21-activated kinase as targets of anti-cancer therapy and discuss the clinical potential of different approaches to modulate RhoA/Rho kinase and p21-activated kinase signaling.
引用
收藏
页码:110 / 124
页数:15
相关论文
共 180 条
[1]  
ABO A, 1997, Patent No. 5698428
[2]  
ABO A, 1996, Patent No. 96020948
[3]  
ABO A, 1997, Patent No. 5605825
[4]  
ABO A, 1996, Patent No. 5518911
[5]   Motility-related proteins as markers for head and neck squamous cell cancer [J].
Abraham, MT ;
Kuriakose, MA ;
Sacks, PG ;
Yee, H ;
Chiriboga, L ;
Bearer, EL ;
Delacure, MD .
LARYNGOSCOPE, 2001, 111 (07) :1285-1289
[6]   Regulation of microfilament reorganization and invasiveness of breast cancer cells by kinase dead p21-activated kinase-1 [J].
Adam, L ;
Vadlamudi, R ;
Mandal, M ;
Chernoff, J ;
Kumar, R .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (16) :12041-12050
[7]   Heregulin regulates cytoskeletal reorganization and cell migration through the p21-activated kinase-1 via phosphatidylinositol-3 kinase [J].
Adam, L ;
Vadlamudi, R ;
Kondapaka, SB ;
Chernoff, J ;
Mendelsohn, J ;
Kumar, R .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (43) :28238-28246
[8]   Oncogenic K-ras drives cell cycle progression and phenotypic conversion of primary pancreatic duct epithelial cells [J].
Agbunag, C ;
Bar-Sagi, D .
CANCER RESEARCH, 2004, 64 (16) :5659-5663
[9]   Bacterial cytotoxins: Targeting eukaryotic switches [J].
Aktories, K ;
Barbieri, JT .
NATURE REVIEWS MICROBIOLOGY, 2005, 3 (05) :397-410
[10]  
ALBERTSSCHONBERG G, 1980, Patent No. 4231938